

efficacy and common tolerability challenges, provided that the studies used for these calculations are similar enough. Number needed to harm (NNH) values may be even more helpful when distinguishing among treatments that are relatively otherwise similar.² The NNH can be for overall tolerability (discontinuation because of an adverse effect) or the occurrence of specific adverse effects of concern for individual patients being treated (such as sedation, weight gain or akathisia). Moreover, ratios of NNH to NNT can provide overall estimates of the risk–benefit trade-offs involved. Finally, we suggest that all of the above concepts are straightforward enough for average clinicians to calculate and understand.^{3,4}

- 1 Roose SP, Rutherford BR, Wall MM, Thase ME. Practising evidence-based medicine in an era of high placebo response: number needed to treat reconsidered. *Br J Psychiatry* 2016; **208**: 416–20.
- 2 Ketter TA, Miller S, Dell’Osso B, Calabrese JR, Frye MA, Citrome L. Balancing benefits and harms of treatments for acute bipolar depression. *J Affect Disord* 2014; **169**: S24–33.
- 3 Citrome L, Ketter TA. When does a difference make a difference? Interpretation of number needed to treat, number needed to harm, and likelihood to be helped or harmed. *Int J Clin Pract* 2013; **67**: 407–11.
- 4 Citrome L, Ketter TA. Teaching the philosophy and tools of evidence-based medicine: misunderstandings and solutions. *Int J Clin Pract* 2009; **63**: 353–9.

Leslie Citrome, Clinical Professor of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, New York USA. Email: citrome@cnsconsultant.com;
Terence A. Ketter, Professor of Psychiatry and Behavioral Sciences

doi: 10.1192/bjp.209.3.262b

Authors’ reply: Drs Citrome and Ketter appear to appreciate the concern we raised about the limitations of applying the NNT from placebo-controlled studies to the clinical situation (where there is no placebo control condition). However, in their letter they maintain that, ‘Indirect comparisons of effect sizes among different medication choices can be quite helpful in ranking interventions for both efficacy and common tolerability challenges, provided that the studies used for these calculations are similar enough’. We do not disagree; in fact, we quoted Garcia in our paper: ‘to directly compare NNTs one needs to ensure that [. . .] the control or comparisons groups to which the treated group was compared were equivalent’.¹

Our point in the paper was that insufficient attention is typically paid to the question of whether control conditions are ‘similar enough’, and we believe this point still holds. Although it is not clear from their letter to what type of situation Drs Citrome and Ketter refer, one is likely on firmest ground when comparing NNTs and NNHs for antidepressant medications calculated from placebo-controlled trials of similar methodology and quality. However, even in this optimal case, it has been established that placebo response can vary significantly from trial to trial, and thus the control conditions for two studies may in fact be less similar than one might suppose.²

Perhaps it would be less problematic to compare the NNTs and NNHs calculated from a comparator trial of two or more antidepressants, because of course in this case there is no issue about the similarity of the studies. The problem is that, to our knowledge, there has not been a consistent finding that one antidepressant has therapeutic superiority or greater tolerability compared with another. One must be careful not to use the NNT and NNH from a single study when that finding has not been replicated, especially since comparator studies are primarily industry-sponsored.

Beyond the specific case of comparing two antidepressant medications, the points made by Citrome and Keller are not relevant to the fundamental thesis of our paper that NNTs calculated from placebo-controlled trials do not inform the clinician’s choice whether to prescribe or not prescribe. Additionally, our further point still stands that NNHs and NNTs

cannot be applied without significant confounding to decisions of whether to prescribe medications or psychotherapy, since the control conditions for these treatments are usually radically different.

- 1 Garcia AM. What does “work” mean? Reopening the debate about clinical significance. *Clin Psychol Sci Pract* 2010; **17**: 48–51.
- 2 Walsh BT, Seidman SN, Sysko R, Gould M. Placebo response in studies of major depression: variable, substantial, and growing. *JAMA* 2002; **287**: 1840–7.

Steven P. Roose, MD, Columbia University College of Physicians and Surgeons, New York State Psychiatric Institute, New York, USA. Email: spr2@cumc.columbia.edu;
Bret R. Rutherford, MD

doi: 10.1192/bjp.209.3.263

Challenges in developing feasible and cost-effective therapies for use in LMICs

Chowdhary *et al* conducted the research reported in their paper¹ under the aegis of PREMIUM (a Program for Mental Health Interventions for Under-Resourced Health systems) in India. They state the overall aim of this programme in their introduction: ‘to investigate a systematic, reproducible method for developing psychological treatments that incorporate global evidence, are contextually appropriate and can be delivered by non-specialist health workers’. In this paper, the authors set out to develop an intervention to be delivered by lay health workers, with the intention of addressing the treatment gap for mental health. The elaborate methodology they adopted to develop this intervention requires a highly skilled research team such as their own. There are simpler and more economical methods for cultural adaptation of evidence-based therapies^{2,3} that have been tested in similar cultures and well described. We are not clear about the rationale for their use of a complex and expensive methodology, given the aim of a ‘reproducible method for developing psychological treatments’. The authors started with a pool of techniques that were considered to be useful. These techniques were mostly based on cognitive–behavioural therapy (CBT). However, based on expert advice, they adapted the manual *Behavioral Activation for Depression: A Clinician’s Guide*. A massive evaluation found this intervention to be unfeasible. Therefore, they further adapted the intervention and tested it in a pilot study. The title of their paper does not reflect the fact that this was an adaptation of an existing intervention and not the development of a new intervention. They used a complex, time-consuming and resource-intensive process that is highly unlikely to be repeatable in low- and middle-income countries (LMICs).

We have adapted CBT for the local population in Pakistan and for the ethnic minority population in England.^{2,3} These methods of adaptation have been described in detail and have been tested for depression⁴ and schizophrenia,^{3,5} and in a guided self-help format for depression.⁶ The methodology evolved over the years, resulting in the development of semi-structured interviews that can be conducted by students and easily analysed using a framework analysis method.⁵ This low-cost methodology is being used in China and the Middle East to adapt CBT. We hope the authors find this work useful in their future attempts to adapt therapy.

The issue of cost becomes even more important in the delivery of therapy. In our two-pronged approach, therapy in secondary care was delivered by psychology graduates (with a typical monthly salary of \$200) and by carers using a culturally adapted CBT-based self-help manual developed locally. No financial help was provided to the carers. We believe it is not just the development or adaptation of an intervention that is important; it should also be deliverable by existing mechanisms. This leads to our second concern: how practical it is to create a new workforce of lay therapists in a low-income country? This lack of understanding of the ground realities has possibly resulted in minimal change

in health settings in LMICs. For example, to the best of our knowledge, the Thinking Healthy programme⁷ – contrary to initial hopes – is not currently being practised in mainstream healthcare in any part of Pakistan. There is a need for researchers in this area to consider the local resources. Otherwise, there is a risk that highly funded programmes will not produce realistic evidence that they can address the treatment gap. We, therefore, believe the paper by Chowdhary *et al* describes a strategy that is not consistent with the current methods of culturally adapting therapy, and one that is too costly to be replicated in LMICs.

- 1 Chowdhary N, Anand A, Dimidjian S, Shinde S, Weobong B, Balaji M, et al. The Healthy Activity Program lay counsellor delivered treatment for severe depression in India: systematic development and randomised evaluation. *Br J Psychiatry* 2015; **208**: 381–8.
- 2 Naeem F, Phiri P, Munshi T, Rathod S, Ayub M, Gobbi M, et al. Using cognitive behaviour therapy with South Asian Muslims: findings from the culturally sensitive CBT project. *Int Rev Psychiatry* 2015; **27**: 233–46.
- 3 Rathod S, Phiri P, Harris S, Underwood C, Thagadur M, Padmanabi U, et al. Cognitive behaviour therapy for psychosis can be adapted for minority ethnic groups: a randomised controlled trial. *Schizophr Res* 2013; **143**: 319–26.
- 4 Naeem F, Gul M, Irfan M, Munshi T, Asif A, Rashid S, et al. Brief culturally adapted CBT (CaCBT) for depression: a randomized controlled trial from Pakistan. *J Affect Disord* 2015; **177**: 101–7.
- 5 Naeem F, Saeed S, Irfan M, Kiran T, Mehmood N, Gul M, et al. Brief culturally adapted CBT for psychosis (CaCBTp): a randomized controlled trial from a low income country. *Schizophr Res* 2015; **164**: 143–8.
- 6 Naeem F, Sarhandi I, Gul M, Khalid M, Aslam M, Anbrin A, et al. A multicentre randomised controlled trial of a carer supervised culturally adapted CBT (CaCBT) based self-help for depression in Pakistan. *J Affect Disord* 2014; **156**: 224–7.
- 7 Rahman A, Malik A, Sikander S, Roberts C, Creed F. Cognitive behaviour therapy-based intervention by community health workers for mothers with depression and their infants in rural Pakistan: a cluster-randomised controlled trial. *Lancet* 2008; **372**: 902–9.

Farooq Naeem. Email: farooqnaeem@yahoo.com; **Shanaya Rathod; Nasar S. Khan; Muhammad Ayub**

doi: 10.1192/bjp.209.3.263a

Author's reply: Naeem *et al* express two concerns regarding the rationale for the work described in our paper on the development and piloting of the Healthy Activity Program (HAP), a brief psychological treatment that can be delivered by non-specialist workers in primary healthcare settings for adults with severe depression:¹ first, that the methodology adopted was expensive and cumbersome; and second, that the delivery of the intervention is not scalable in terms of human resources.

The goal of the PREMIUM approach was to design a treatment that was based on both contextual as well as global evidence, and that could be delivered by non-specialist workers in routine healthcare settings.² In both these ways, the PREMIUM approach is distinct from that adopted by Naeem and colleagues, whose trials adapted an existing psychotherapy package and evaluated the treatment in tertiary facilities or in psychiatric out-patients in large urban settings that cater to an unrepresentative and tiny fraction of the population burden of mental disorders. Our finding that behavioural activation was the most appropriate theoretical approach for treatment was a consequence of our methodology rather than an *a priori* decision and is, in fact, a significant scientific contribution in its own right in two ways: first, in the light of the approach taken, it demonstrates that this theory has cross-cultural validity; and second, it shows that there is no need for the more cumbersome cognitive components of the full package of CBT, a finding that is aligned with the common elements approach being increasingly favoured as a key strategy for the dissemination of psychological treatments.³ It is true that the methodology we adopted was time-consuming, as we were not to know when we started that our final output would resemble an

established psychological treatment; it is as the result of this experience that we have been to identify those steps of the PREMIUM methodology that are crucial to designing scalable treatments, reducing the resource requirements for replicating this approach for other mental health conditions.²

With regard to scaling up of empirically supported psychological treatments, it is absolutely correct that the treatments should be designed to be deliverable by existing health personnel. This was precisely the goal of PREMIUM. The problems of scaling up psychological treatments are not unique to LMICs; indeed, there is virtually no country in the world in which it has happened, even those with abundant mental health professionals, barring exceptions such as the UK's Improving Access to Psychological Therapies (IAPT) programme. The human resources that deliver treatments such as HAP and the Thinking Healthy Programme (THP),⁴ which Naeem *et al* allude to, are in plentiful supply in all countries, significantly more so than mental health professionals, and the next challenge for our field is to scale up these empirically supported treatments in the real world. This goal is being facilitated by a number of new opportunities, including the collaborative hubs for scaling up evidence-based mental health interventions established by the US National Institute of Mental Health (<http://grants.nih.gov/grants/guide/pa-files/PAR-16-174.html>) and its ongoing support for evaluating the delivery of the THP through peers in India and Pakistan;⁵ the World Health Organization's programme on low-intensity psychological treatments, which has adopted the THP to be scaled up through its Mental Health Gap Action Programme (mhGAP) and is being implemented in dozens of countries around the world; and national policy initiatives, such as in India, to reorient community health workers to deliver mental healthcare. It would be fair to say that it is precisely the systematic development of interventions such as the THP and HAP, with exquisite sensitivity to context and embedding in front-line healthcare delivery platforms, and their subsequent evaluation in definitive trials with impressive clinical results (the HAP definitive trial is currently in review)⁶ that has fuelled these initiatives. It remains a mystery why Naeem *et al* believe that their approach, focused on tertiary facilities in urban areas and provision by mental health professionals, is more scalable than the approach of task-sharing by primary and community health workers championed by global mental health, and exemplified by the methodology used to design the THP and HAP.

- 1 Chowdhary N, Anand A, Dimidjian S, Shinde S, Weobong B, Balaji M, et al. The Healthy Activity Program lay counsellor delivered treatment for severe depression in India: systematic development and randomised evaluation. *Br J Psychiatry* 2016; **208**: 381–8.
- 2 Vellakkal S, Patel V. Designing psychological treatments for scalability: the PREMIUM approach. *PLoS ONE* 2015; **10**: e0134189.
- 3 Bolton P, Lee C, Haroz EE, Murray L, Dorsey S, Robinson C, et al. A transdiagnostic community-based mental health treatment for comorbid disorders: development and outcomes of a randomized controlled trial among Burmese refugees in Thailand. *PLoS Med* 2014; **11**: e1001757.
- 4 Rahman A, Malik A, Sikander S, Roberts C, Creed F. Cognitive behaviour therapy-based intervention by community health workers for mothers with depression and their infants in rural Pakistan: a cluster-randomised controlled trial. *Lancet* 2008; **372**: 902–9.
- 5 Singla D, Lazarus A, Atif N, Sikander S, Bhatia U, Ahmad I, et al. "Someone like us": delivering maternal mental health through peers in two South Asian contexts. *J Affect Disord* 2014; **168**: 452–8.
- 6 Patel V, Weobong B, Nadkarni A, Weiss HA, Anand A, Naik S, et al. The effectiveness and cost-effectiveness of lay counsellor-delivered psychological treatments for harmful and dependent drinking and moderate to severe depression in primary care in India: PREMIUM study protocol for randomized controlled trials. *Trials* 2014; **15**: 101.

Vikram Patel, FMedSci, Sangath, Goa, Centre for Chronic Conditions and Injuries, Public Health Foundation of India, New Delhi, India and London School of Hygiene & Tropical Medicine, London, UK. Email: vikram.patel@lshtm.ac.uk

doi: 10.1192/bjp.209.3.264